9 completed, 8 recruiting, 4 active not recruiting, 4 not yet recruiting. 12 Phase 2, 7 Phase 3, 5 Phase 1, 4 Phase 4, 1 Early Phase 1.
Follow inebilizumab: new trials by email Literature Review of inebilizumab trials Research Report on inebilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 38 | 2026-12-01 | 2026-07-24 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD Inebilizumab - Immunoglobulin G4-related Disease | Phase 2 | Not yet recruiting | Amgen | 15 | 2026-10-31 | 2026-08-27 |
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous | Phase 3 | Recruiting | Amgen | 159 | 2026-10-01 | 2026-10-01 |
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Rituximab (R), Eculizumab (Soliris®), Ravulizumab - NMOSD | Phase 4 | Recruiting | Massachusetts General Hospital | 540 | 2026-09-01 | 2026-09-24 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Inebilizumab - Generalized Myasthenia Gravis | Phase 2 | Recruiting | Amgen | 15 | 2026-07-21 | 2026-10-23 |
| Inebilizumab for the Treatment of Patients With Type 1 Autoimmune Pancreatitis Inebilizumab - Type 1 AIP | Phase 4 | Recruiting | Ruijin Hospital | 50 | 2025-10-01 | 2026-10-07 |
| Inectolizumab With Steroid Optimization in Newly Treated NMOSD Inebilizumab + Rapid Steroid Tapering group, Inebilizumab + Standard Steroid Tapering group - Neuromyelitis Optica, Autoimmune Diseases | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 25 | 2025-09-01 | 2025-09-08 |
| Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD Slow-tapering glucocorticoids + Inebilizumab, Rapid-tapering glucocorticoids + Inebilizumab - Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 3 | Not yet recruiting | Tianjin Medical University General Hospital | 170 | 2025-09-01 | 2025-08-20 |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases Inebilizumab, Blinatumomab - Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis | Phase 2 | Recruiting | Amgen | 220 | 2025-07-16 | 2026-10-05 |
| Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders Inebilizumab, oral immunosuppressant - Neuromyelitis Optica Spectrum Disorder | Unknown | Xuanwu Hospital, Beijing | 50 | 2024-07-09 | 2024-09-19 | |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Active not recruiting | Amgen | 32 | 2024-04-02 | 2025-11-21 |
| A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Inebilizumab - Neuromyelitis Optica Spectrum Disorders | Phase 4 | Unknown | Hansoh BioMedical R&D Company | 33 | 2024-02-25 | 2024-01-18 |
| Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders Inebilizumab, Rituximab(RTX) - Neuromyelitis Optica Spectrum Disorders | Unknown | Feng Jinzhou | 80 | 2023-10-20 | 2023-10-05 | |
| Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 | Recruiting | Amgen | 15 | 2023-07-03 | 2025-12-05 |
| A Study of MT-0551 in Patients With Systemic Sclerosis Inebilizumab, Placebo - Systemic Sclerosis | Phase 3 | Active not recruiting | Tanabe Pharma Corporation | 80 | 2022-07-20 | 2025-12-08 |
| The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Inebilizumab, Placebo - Autoimmune Encephalitis, Encephalitis | Phase 2 | Recruiting | University of Utah | 116 | 2022-03-30 | 2025-07-01 |
| A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease Inebilizumab, Placebo - IgG4 Related Disease | Phase 3 | Active not recruiting | Amgen | 135 | 2020-12-04 | 2025-12-11 |
| Myasthenia Gravis Inebilizumab Trial inebilizumab, IV Placebo - Myasthenia Gravis | Phase 3 | Active not recruiting | Amgen | 238 | 2020-10-15 | 2026-05-15 |
| Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor Inebilizumab, VIB4920, Inebilzumab+VIB4920 - Highly Sensitized Patients on Waiting List for Kidney Transplantation | Phase 2 | Withdrawn | Amgen | 2019-12-27 | 2024-06-21 |
Showing 20 of 29. Sign in to see all of them.
Neuromyelitis Optica (8) · Lymphoma, Non-Hodgkin (3) · Immunoglobulin G4-Related Disease (2) · Myasthenia Gravis (2) · Recurrence (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Autoimmune Pancreatitis (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Encephalitis (1) · Fatigue (1) · Fatigue Syndrome, Chronic (1) · Glomerulonephritis, Membranous (1)
Amgen (10) · MedImmune LLC (7) · AstraZeneca (1) · Charite University, Berlin, Germany (1) · Feng Jinzhou (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Hansoh BioMedical R&D Company (1) · Massachusetts General Hospital (1) · Ruijin Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Tanabe Pharma Corporation (1) · Tianjin Medical University General Hospital (1) · University of Utah (1) · Xuanwu Hospital, Beijing (1)
United States (20) · Spain (11) · Poland (10) · Canada (9) · Germany (9) · China (8) · France (8) · Italy (7) · Hungary (5) · Japan (5) · Turkey (Türkiye) (5) · United Kingdom (5) · Argentina (4) · Belgium (4) · Brazil (4)
Armando Flor (1) · Carol Ann Huff, MD (1) · Duowu Zou, Doctor (1) · Jinzhou Feng, Ph.D (1) · Judith Bellmann-Strobl, MD (1) · Junwei Hao, MD (1) · Philippe-Antoine Bilodeau, MD (1) · Stacey L Clardy, MD, PhD (1)
PMID 27267753, PMID 31495497, PMID 11113214, PMID 12393404, PMID 15564716, PMID 15817019, PMID 17262855, PMID 17538176, PMID 18417336, PMID 18851928, PMID 19680671, PMID 20427647, PMID 20605905, PMID 20829370, PMID 21163445, PMID 21865579, PMID 23151040, PMID 23290630, PMID 24360484, PMID 24763533, PMID 25392198, PMID 25573986, PMID 26187412, PMID 26666258, PMID 27399303, PMID 27412413, PMID 27575749, PMID 27886126, PMID 29143550, PMID 29159189, PMID 29293273, PMID 29406578, PMID 29476014, PMID 29549218, PMID 29956883, PMID 30578370, PMID 30675918, PMID 31292262, PMID 31900318, PMID 32052483, PMID 33538237, PMID 33724534, PMID 33771837, PMID 35158461, PMID 36370634, PMID 37221052, PMID 37792260, PMID 38760098, PMID 39222408, PMID 39541094
2025 (4), 2023 (2), 2009 (1), 2014 (1)